Evidence map›Paper›PMID 31430394›Full record

ArticleJournal of the American Geriatrics Society2019

Advancing the Science of Deprescribing: A Novel Comprehensive Conceptual Framework.

Amy Linsky, Walid F Gellad, Jeffrey A Linder, Mark W Friedberg

2 registry-linked trialsOpen access · greenAbstract read
In one paragraph

Article in Journal of the American Geriatrics Society, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 59 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed, 4 pooled it
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06446349 narecruitingnot on this mapstarted 2024, after this paper: background citation

Impact of Identification and Brief Motivational Intervention in Dispensing Pharmacies (BMI) on the Deprescription of Benzodiazepines and Related Substances in Adult Chronic Drug Users

TypeinterventionalSponsorUniversity Hospital, GrenobleRan2024 to 2026Enrolled300ConditionsBenzodiazepine WithdrawalArmsBrief motivational intervention
NCT06771999 narecruitingnot on this mapstarted 2025, after this paper: background citation

Attitudes Towards Deprescribing of Non-oncologic Medication in Cancer Pacient and the Impact of an Educational Intervention by a Clinical Pharmacist

TypeinterventionalSponsorIuliu Hatieganu University of Medicine and PharmacyRan2025 to 2027Enrolled120ConditionsPalliative Care, CancerArmsEducational intervention by a clinical pharmacist
3 · Its place in the literature

Who cites it

59 citing papers in PubMed, 4 syntheses or guidelines pooled it, 104 citations in OpenAlex.

  1. Pooled it
  2. Consumer Attitudes Towards Deprescribing: A Systematic Review and Meta-Analysis.The journals of gerontology. Series A, Biological sciences and medical sciences · 2022
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Article
  9. Article
  10. Article
  11. Trajectories of Medication Use Prior to Death in US Nursing Home Residents With Dementia.Journal of the American Medical Directors Association · 2026
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Pharmacy (Basel, Switzerland) · 2025
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 1 country.

Amy LinskyGeneral Internal Medicine, VA Boston Healthcare System and Boston University School of Medicine, Boston, Massachusetts.ORCID 0000-0002-8090-3431
Walid F GelladUniversity of Pittsburgh and the VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania.
Jeffrey A LinderDivision of General Internal Medicine and Geriatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Mark W FriedbergRAND, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts.
Boston University · USBrigham and Women's Hospital · USNorthwestern University · USUniversity of Pittsburgh · US

Funding

Application of Economics & Social psychology to improve Opioid Prescribing Safety (AESOPS) TrialR21AG057395 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI DOCTOR, JASON N., SULLIVAN, MARK D · 2017 to 2018
$494k
Behavioral Economics Applications to Geriatrics Leveraging EHRs (BEAGLE)R21AG057383 · NIA · NORTHWESTERN UNIVERSITY AT CHICAGO · PI PERSELL, STEPHEN · 2017 to 2018
$463k
Improving Quality & Equity of Emergency Care Decisions (IQED)R21AG057400 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI MEEKER, DANIELLA · 2017 to 2018
$461k
Reducing High-Risk Geriatric Polypharmacy via EHR NudgesR21AG057396 · NIA · RAND CORPORATION · PI FRIEDBERG, MARK WILLIAM · 2017 to 2018
$455k
Patient and provider perceptions of intentional medication discontinuationIK2HX001357 · VA · VA BOSTON HEALTH CARE SYSTEM · PI LINSKY, AMY · 2018 to 2019
–
AHRQ HHS HHSP233201500020IAHRQ HHS R01 HS024930AHRQ HHS R01 HS026506HSRD VA IK2 HX001357NIA NIH HHS R21 AG057383NIA NIH HHS R21AG057383NIA NIH HHS R21 AG057395NIA NIH HHS R21 AG057396NIA NIH HHS R21AG057396NIA NIH HHS R21 AG057400NIA NIH HHS R21AG057400NIDA NIH HHS R21AG057395
6 · The paper itself

Abstract

Polypharmacy is common in older adults and associated with inappropriate medication use, adverse drug events, medication nonadherence, higher costs, and increased mortality compared with those without polypharmacy. Deprescribing, the clinically supervised process of stopping or reducing the dose of medications when they cause harm or no longer provide benefit, may improve outcomes. Although potentially beneficial, clinicians struggle to overcome structural, organizational, technological, and cognitive barriers to deprescribing, limiting its use in clinical practice. Deprescribing science would benefit from a unifying conceptual framework to prioritize research. Current deprescribing conceptual frameworks have made important contributions to the field but often with a focus on specific medication classes or aspects of deprescribing. To further this relatively nascent field, we developed a broader deprescribing conceptual framework that builds on prior frameworks and includes patient, prescriber, and system influences; the process of deprescribing; outcomes; and dissemination. Patient factors include patients' biology, experience, values, and preferences. Prescriber factors include rational (eg, based on explicit knowledge) and nonrational (eg, behavioral tendencies, biases, and heuristics) decision making. System factors include resources, incentives, goals, and culture that contribute to deprescribing. The framework separates the deprescribing decision from the deprescribing process. The framework captures the results of deprescribing by examining changes in clinical structures, performance processes, patient experience, health outcomes, and cost. Through testing and refinement, this novel, more comprehensive conceptual framework has the potential to advance deprescribing research by organizing the existing evidence, identifying evidence gaps, and categorizing deprescribing interventions and the settings in which they are applied. J Am Geriatr Soc 67:2018-2022, 2019.

Indexed as

DeprescriptionsOutcome and Process Assessment, Health CareDrug-Related Side Effects and Adverse ReactionsHumansModels, TheoreticalPolypharmacybehavioral economicsclinical decision makinghealth services for older adultsimplementation sciencepolypharmacy

Identifiers

PMID31430394
PMCPMC6800794
OpenAlexW2969289502

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.